Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice

Gene Therapy

Volumn 13, Issue 1, 2006, Pages 60-66

  Dwyer, R M ^a   Bergert, E R ^a   O'Connor, M K ^a   Gendler, S J ^b   Morris, John C ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c NONE   (United States)

Author keywords

MUC1; Ovarian cancer; Radioiodine; Sodium iodide symporter

Indexed keywords

ADENOVIRUS VECTOR; IODINE 123; IODINE 131; MUCIN 1; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG DOSE REGIMEN; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS;

EID: 29244483087     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302599     Document Type: Article

References (38)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Ozols RF, Bookman MA, Connolly DC, Daly MB, Goldwin AK, Schilder RJ et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5: 19-24.
3. NIH Consensus Conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273: 491-497.
4. Ozols RF. Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 2000; 27: 47-49.
5. Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y et al. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001; 14: 165-171.
6. Gaducci A, Cosio S, Muraca S, Genazzani A. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: Biological data and clinical implications. Eur J Gynaecol Oncol 2002; 23: 390-396.
7. Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstet Gynecol 1998; 91: 783-792.
8. Dohan O, Carrasco N. Advances in Na+/I- symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 2003; 213: 59-70.
9. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CYF et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524-1531.
10. +/I-symporters for radioiodide concentrator gene therapy. J Nucl Med 2000; 41: 1898-1904.
11. Boland A, Marcel R, Opolon P, Bidart J-M, Yeh P, Filetti S et al. Adenovirus-mediated transfer of the thyroid sodium-iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484-3492.
12. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ. Genetically targeted radiotherapy for multiple myeloma. Gene Therapy 2003; 102: 489-496.
13. Cho J-Y, Shen DHY, Yang W, Williams B, Buckwalter TLF, LaPerle KMD et al. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Therapy 2002; 9: 1139-1145.
14. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 2002; 13: 1723-1735.
15. Carlin S, Cunningham SH, Boyd M, McCluskey AG, Mairs RG. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: Effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Ther 2000; 7: 1-8.
16. 2PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003; 15: 7840-7844.
17. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts following MUC1-driven expression of the sodium iodide symporter (NIS). Clin Cancer Res 2005; 11: 1483-1489.
18. Ichige K, Perry L, Vogel CA, Buchegger F, Kufe D. Expression of the DF3-P epitope in human ovarian carcinomas. Clin Cancer Res 1995; 1: 565-571.
19. Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumors. J Pathol 1997; 183: 311-317.
20. Stimpfl M, Schmid BC, Schiebel I, Tong D, Leodolter S, Obermair A et al. Expression of mucins and cytokeratins in ovarian cancer cell lines. Cancer Lett 1999; 145: 133-141.
21. Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 gene products in human ovarian carcinomas. Jpn J Clin Oncol 2002; 32: 525-529.
22. Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger JT, Hermann M et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Therapy 2002; 9: 1093-1100.
23. You Z, Fischer DC, Tong X, Hasenberg A, Aguilar-Cordova E, Kieback DG. Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther 2001; 8: 168-175.
24. Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 1996; 23: 154-158.
25. MIRD dose estimate report No. 5: Summary of current radiation dose estimates to humans from 123I, 124I, 126I, 130I, 131I and 132I as sodium iodide. J Nucl Med 1975; 16: 857-860.
26. Mazzaferri E, Kloos R. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-1463.
27. Wapnir IL, Van DeRijn M, Nowels K, Amenta PS, Walton K, Montgomery K et al. Immunohistochemical profile of the human sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 2003; 88: 1880-1888.
28. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59: 661-668.
29. Tai Y-T, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 1999; 59: 2121-2126.
30. Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001; 7: 2496-2504.
31. Ring C, Blouin P, Martin L-A, Hurst HC, Lemoine NR. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumor-selective expression of a prodrug activating enzyme. Gene Therapy 1997; 4: 1045-1052.
32. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
33. Kanerva A, Bauerschmitz GJ, Yamamoto T, Lam JT, Alvarez RD, Siegal GP et al. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Therapy 2004; 11: 552-559.
34. Breidenbach M, Rein DT, Wang M, Nettelback DM, Hemminki A, Ulasov I et al. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Therapy 2004; 15: 509-518.
35. Wu H, Han T, Lam JT, Leath CA, Dmitrev I, Kashentseva E et al. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy. Gene Therapy 2004; 11: 874-878.
36. Weiss S, Philip N, Grollman E. Iodine transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984; 114: 1090-1098.
37. Spitzweg C, Zhang Z, Bergert ER, Castro MR, McIver B, Heufelder AE et al. Prostate-specific antigen promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999; 59: 2136-2141.
38. Castro RM, Bergert ER, Beito TG, McIver B, Goellner JR, Morris JC. Development of monoclonal antibodies against the human sodium iodide symporter: Immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab 1999; 84: 2957-2962.